Publication

Article

Pharmacy Times

October 2015 Diabetes
Volume81
Issue 10

Generic Product News (October 2015)

Read about the new generic products featured in October.

Lupin Pharmaceuticals

Compare to: Cymbalta (Eli Lilly & Company)

Indication: Lupin Pharmaceuticals has launched Duloxetine Delayed Release Capsules, the generic equivalent of Lilly’s Cymbalta, in a 40-mg dosage strength. Lupin Pharmaceuticals is currently the only manufacturer to provide this product in 40-mg capsules. Duloxetine is indicated to treat or manage major depressive disorder, generalized anxiety disorder, and diabetic peripheral neuropathic pain.

Dosage Form: Capsules: 20, 30, 40, and 60 mg

For More Information: www.lupinpharmaceuticals.com

Piperacillin and Tazobactam for Injection USPMarketed by: Mylan

Compare to: Zosyn (Pfizer)

Indication: Mylan has launched Piperacillin and Tazobactam for Injection USP, the generic equivalent of Zosyn Injection. It is a combination penicillin-class antibacterial and betalactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria.

Dosage Form: Single-dose vials: 3.375 g

For More Information: www.mylan.com

Voriconazole Tablets, 50 mg and 200 mgMarketed by: Glenmark Pharmaceuticals, Inc

Compare to: Vfend (Pfizer)

Indication: Glenmark has received FDA approval of Voriconazole Tablets, the generic equivalent of Pfizer’s antifungal agent Vfend, in 50-mg and 200- mg strengths. Voriconazole is indicated to treat invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients, and infection with other serious fungal pathogens, including Scedosporium apiospermum and Fusarium species in patients 12 years or older.

Dosage Form: Tablets: 50 and 200 mg

For More Information: www.glenmarkpharma.com

Rivastigmine Transdermal SystemMarketed by: Sandoz

Compare to: Exelon (Novartis)

Indication: Sandoz has launched a generic version of Novartis’ Exelon Patch for Alzheimer’s dementia. The generic rivastigmine transdermal system is the only patch indicated to treat mild, moderate, and severe memory problems associated with Alzheimer’s disease. The patch can also be used to treat patients with mild to moderate dementia associated with Parkinson’s disease.

Dosage Form: Patch: 4.6 mg/24 hours

For More Information: www.sandoz.com

Alprazolam TabletsMarketed by: Aurobindo Pharma Ltd

Compare to: Xanax (Pfizer)

Indication: Aurobindo Pharma Ltd has received FDA approval for Alprazolam tablets, a benzodiazepine drug that is the generic version of Pfizer’s Xanax. Alprazolam tablets work to slow down the movement of chemicals in the brain that may become unbalanced. The product is indicated to treat anxiety disorders, panic disorders, and anxiety caused by depression.

Dosage Forms: Tablets: 0.25, 0.5, 1, and 2 mg

For More Information: www.aurobindo.com

TelmisartanMarketed by: Amneal

Compare to: Micardis (Boehringer Ingelheim)

Indication: Amneal has received FDA approval of Telmisartan Tablets, a generic version of Micardis. The medication is an angiotensin 2—receptor blocker indicated for the treatment of hypertension. Amneal will market telmisartan in 20-, 40-, and 80-mg tablets, which are the same strengths as the brand product.

Dosage Form: Tablets: 20, 40, and 80 mg

For More Information: www.amneal.com

Drospirenone and Ethinyl Estradiol Tablets USPMarketed by: Mylan

Compare to: Yasmin (Bayer)

Indication: Mylan has launched Drospirenone and Ethinyl Estradiol Tablets USP, a generic version of Bayer’s Yasmin tablets, in a 3 mg/0.03 mg dose. The product is indicated to prevent pregnancy in women.

Dosage Form: Tablets: 3 mg/0.03 mg

For More Information: www.mylan.com

Balsalazide Disodium TabletsMarketed by: Par Pharmaceutical

Compare to: Giazo (Salix)

Indication: Par Pharmaceutical has received FDA approval of Balsalazide Disodium Tablets, the generic equivalent of Salix’s Giazo. The medication is a locally acting aminosalicylate for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years and older. The recommended dose is three 1.1-g tablets 2 times a day (6.6 g/day) with or without food for up to 8 weeks.

Dosage Form: Tablets: 1.1 g

For More Information: www.parpharm.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs